Acute Lymphocytic Leukemia
4/17/00 (Del Rio)
Group: Monday Residents
RE: A 46 year old hispanic female with prior history of ALL and recent 2 day onset of facial parasthesia.
Question: What bearing do recent discoveries about acute lymphocytic leukemia have on diagnosis and treatment?
<12>
Link Directly to Fulltext article in Ovid
Unique Identifier: 98372453
Authors: Pui CH. Evans WE.
Institution: St. Jude Children's Research Hospital, College of Medicine, University of Tennessee, Memphis 38105-0318, USA.
Title: Acute lymphoblastic leukemia. [Review] [105 refs]
Source: New England Journal of Medicine. 339(9):605-15, 1998 Aug 27.
Registry Numbers: 0 (DNA-Binding Proteins). 0 (Oncogene Proteins, Fusion). 149025-06-9 (HRX protein).
<7>
Unique Identifier: 99109022
Authors: O'Connor OA. Weiss M.
Institution: Memorial Sloan Kettering Cancer Center, Department of Medicine, Cornell University Medical Center, New York,: New York 10021, USA.
Title: Recent advances in the biology and management of acute lymphoblastic leukemia in adults. [Review] [133 refs]
Source: Cancer Treatment & Research. 99:307-33, 1999.
<16>
Unique Identifier: 96371905
Authors: Levitt L. Lin R.
Institution: Department of Medicine, Stanford University School of Medicine, California, USA.
Title: Biology and treatment of adult acute lymphoblastic leukemia. [Review] [135 refs]
Source: Western Journal of Medicine. 164(2):143-55, 1996 Feb.
Abstract: The molecular analysis of acute lymphoblastic leukemia (ALL) has provided exciting insights into the pathogenesis of: this disease. This disease is heterogenous and can be subtyped based on chromosomal, immunophenotypic, and: structural criteria. The varying prognostic implications of different ALL subtypes markedly influence the treatment: decisions in adults. Many patients with T-cell ALL can be cured with chemotherapy alone. In contrast, patients with: early B-lineage ALL with certain chromosomal abnormalities, especially the Philadelphia chromosome, do not have: durable responses to chemotherapy and should receive a bone marrow transplantation if an HLA-matched donor is: available. Recent reports have shown improved results for adults with B-cell ALL (Burkitt's) after intensive alternating: cycles of chemotherapy containing high doses of methotrexate and cyclophosphamide. Future clinical and laboratory: investigation should lead to the development of novel and possibly more effective treatments specifically tailored for: different subsets of ALL. [References: 135]
Registry Numbers: 0 (Antineoplastic Agents).
[litsrch99/footer_generic.html]